Oric Historical Financial Ratios
| ORIC Stock | USD 9.80 0.07 0.71% |
Oric Pharmaceuticals is promptly reporting on over 91 different financial statement accounts. To analyze all of these accounts together requires a lot of time and effort. However, using these accounts to derive some meaningful and actionable indicators such as Days Sales Outstanding of 0.0 will help investors to properly organize and evaluate Oric Pharmaceuticals financial condition quickly.
Oric |
About Oric Financial Ratios Analysis
Oric PharmaceuticalsFinancial ratios are relationships based on a company's financial information. They can serve as useful tools to evaluate Oric Pharmaceuticals investment potential. Financial ratio analysis can also be defined as the process of presenting financial ratios, which are mathematical indicators calculated by comparing key financial information appearing on Oric financial statements. Financial ratios are useful tools that help investors analyze and compare relationships between different pieces of financial information across Oric Pharmaceuticals history.
Oric Pharmaceuticals Financial Ratios Chart
Add Fundamental
Payables Turnover
A liquidity ratio that shows how quickly a company pays off its suppliers by dividing total purchases by average accounts payable.Return On Equity
Return on Equity is the amount of Oric Pharmaceuticals net income returned as a percentage of Oric Pharmaceuticals equity. Return on equity measures Oric Pharmaceuticals profitability by revealing how much profit Oric Pharmaceuticals generates with the money shareholders have invested. A measure of the profitability of a business in relation to the equity, calculated by dividing net income by shareholder's equity.Most ratios from Oric Pharmaceuticals' fundamentals are interrelated and interconnected. However, analyzing fundamentals ratios one by one will only give a small insight into Oric Pharmaceuticals current financial condition. On the other hand, looking into the entire matrix of fundamentals ratios, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Oric Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product. For information on how to trade Oric Stock refer to our How to Trade Oric Stock guide.At present, Oric Pharmaceuticals' Income Quality is projected to slightly decrease based on the last few years of reporting. The current year's Current Ratio is expected to grow to 18.35, whereas PTB Ratio is forecasted to decline to 2.01.
| 2021 | 2022 | 2023 | 2024 (projected) | Current Ratio | 15.87 | 13.68 | 10.39 | 18.35 | Net Debt To EBITDA | 2.87 | 0.7 | 0.12 | 0.11 |
Oric Pharmaceuticals fundamentals Correlations
Click cells to compare fundamentals
Oric Pharmaceuticals Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Oric Pharmaceuticals fundamentals Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Ptb Ratio | 8.76 | 2.56 | 2.04 | 1.05 | 2.11 | 2.01 | |
| Book Value Per Share | 2.94 | 13.21 | 7.19 | 5.61 | 4.36 | 3.52 | |
| Free Cash Flow Yield | (0.0315) | (0.0618) | (0.11) | (0.33) | (0.18) | (0.19) | |
| Operating Cash Flow Per Share | (0.79) | (2.06) | (1.57) | (1.89) | (1.67) | (1.75) | |
| Capex To Depreciation | 0.58 | 0.75 | 0.69 | 1.05 | 2.15 | 0.82 | |
| Pb Ratio | 8.76 | 2.56 | 2.04 | 1.05 | 2.11 | 2.01 | |
| Free Cash Flow Per Share | (0.81) | (2.09) | (1.59) | (1.95) | (1.68) | (1.77) | |
| Roic | (0.31) | (0.34) | (0.29) | (0.42) | (0.49) | (0.52) | |
| Net Income Per Share | (0.85) | (4.43) | (2.05) | (2.31) | (1.96) | (2.06) | |
| Payables Turnover | 6.58 | 1.28 | 0.48 | 0.73 | 1.09 | 2.07 | |
| Cash Per Share | 2.98 | 13.38 | 6.24 | 5.2 | 4.05 | 3.99 | |
| Pocfratio | (32.75) | (16.41) | (9.37) | (3.11) | (5.52) | (5.8) | |
| Capex To Operating Cash Flow | (0.0326) | (0.0147) | (0.0158) | (0.0277) | (0.009908) | (0.0104) | |
| Pfcf Ratio | (31.71) | (16.17) | (9.22) | (3.02) | (5.47) | (5.74) | |
| Days Payables Outstanding | 55.48 | 284.85 | 767.44 | 498.76 | 333.88 | 286.0 | |
| Income Quality | 0.88 | 0.61 | 0.76 | 0.84 | 0.85 | 0.92 | |
| Roe | (0.29) | (0.34) | (0.28) | (0.41) | (0.45) | (0.47) | |
| Ev To Operating Cash Flow | (28.96) | (14.67) | (5.61) | (2.25) | (5.37) | (5.64) | |
| Pe Ratio | (30.24) | (7.64) | (7.18) | (2.55) | (4.7) | (4.94) | |
| Return On Tangible Assets | (0.27) | (0.33) | (0.26) | (0.37) | (0.4) | (0.42) | |
| Ev To Free Cash Flow | (28.04) | (14.46) | (5.52) | (2.19) | (5.32) | (5.58) | |
| Earnings Yield | (0.0331) | (0.13) | (0.14) | (0.39) | (0.21) | (0.22) | |
| Net Debt To E B I T D A | 3.24 | 1.06 | 2.87 | 0.7 | 0.12 | 0.11 | |
| Current Ratio | 16.81 | 32.96 | 15.87 | 13.68 | 10.39 | 18.35 | |
| Tangible Book Value Per Share | 2.94 | 13.21 | 7.28 | 5.69 | 4.36 | 3.54 | |
| Graham Number | 7.51 | 36.29 | 18.2 | 17.06 | 13.85 | 12.1 | |
| Shareholders Equity Per Share | 2.94 | 13.21 | 7.19 | 5.61 | 4.36 | 3.52 | |
| Capex Per Share | 0.0257 | 0.0304 | 0.0247 | 0.0524 | 0.0165 | 0.0221 | |
| Graham Net Net | 2.78 | 12.96 | 5.57 | 4.58 | 3.5 | 3.03 | |
| Enterprise Value Over E B I T D A | (24.74) | (8.95) | (4.28) | (1.85) | (4.19) | (4.4) | |
| Price Earnings Ratio | (30.24) | (7.64) | (7.18) | (2.55) | (4.7) | (4.94) | |
| Price Book Value Ratio | 8.76 | 2.56 | 2.04 | 1.05 | 2.11 | 2.01 | |
| Price Earnings To Growth Ratio | 1.25 | (0.0181) | 0.13 | (0.2) | 0.31 | 0.19 | |
| Days Of Payables Outstanding | 55.48 | 284.85 | 767.44 | 498.76 | 333.88 | 286.0 | |
| Price To Operating Cash Flows Ratio | (32.75) | (16.41) | (9.37) | (3.11) | (5.52) | (5.8) | |
| Price To Free Cash Flows Ratio | (31.71) | (16.17) | (9.22) | (3.02) | (5.47) | (5.74) | |
| Ebt Per Ebit | 0.94 | 0.99 | 1.0 | 0.97 | 0.91 | 1.06 | |
| Effective Tax Rate | 0.052 | (0.32) | 0.0132 | (0.0264) | (0.0304) | (0.0319) | |
| Company Equity Multiplier | 1.07 | 1.03 | 1.09 | 1.11 | 1.12 | 0.67 | |
| Return On Capital Employed | (0.32) | (0.26) | (0.28) | (0.4) | (0.48) | (0.5) |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Oric Pharmaceuticals offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Oric Pharmaceuticals' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Oric Pharmaceuticals Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Oric Pharmaceuticals Stock:Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Oric Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product. For information on how to trade Oric Stock refer to our How to Trade Oric Stock guide.You can also try the Price Exposure Probability module to analyze equity upside and downside potential for a given time horizon across multiple markets.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Oric Pharmaceuticals. If investors know Oric will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Oric Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.87) | Return On Assets (0.29) | Return On Equity (0.46) |
The market value of Oric Pharmaceuticals is measured differently than its book value, which is the value of Oric that is recorded on the company's balance sheet. Investors also form their own opinion of Oric Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Oric Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Oric Pharmaceuticals' market value can be influenced by many factors that don't directly affect Oric Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Oric Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Oric Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Oric Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.